The current guidelines for chronic myeloid leukemia (CML) endorse the tyrosine kinase inhibitors (TKIs) imatinib, nilotinib and dasatinib for front-line therapy of CML in chronic phase (CP) and, consequently, physicians and patients face a difficult choice. There is no difference in overall survival between these TKIs. Choice of front-line treatment should be based on additional considerations: age, prognostic category, safety of the drug, the possibility of a deep and sustained response (treatment free remission, TFR). Whatever TKI is used first, current guidelines include milestones of optimal response (and failure) earlier than before, and a timely monitoring and treatment optimization, as early as after three months from starting front-line treatment, drives the treatment strategy. If the most important end point of treatment is overall survival, and the definitive cure of CML remains elusive for most patients, a survival free of treatment, a “treatment free remission”, may be achievable and may be particularly attractive for younger patients.

Chronic myeloid leukemia. Drug selection in first-line therapy and beyond

Gianantonio Rosti
;
Gabriele Gugliotta;Fausto Castagnetti
2014

Abstract

The current guidelines for chronic myeloid leukemia (CML) endorse the tyrosine kinase inhibitors (TKIs) imatinib, nilotinib and dasatinib for front-line therapy of CML in chronic phase (CP) and, consequently, physicians and patients face a difficult choice. There is no difference in overall survival between these TKIs. Choice of front-line treatment should be based on additional considerations: age, prognostic category, safety of the drug, the possibility of a deep and sustained response (treatment free remission, TFR). Whatever TKI is used first, current guidelines include milestones of optimal response (and failure) earlier than before, and a timely monitoring and treatment optimization, as early as after three months from starting front-line treatment, drives the treatment strategy. If the most important end point of treatment is overall survival, and the definitive cure of CML remains elusive for most patients, a survival free of treatment, a “treatment free remission”, may be achievable and may be particularly attractive for younger patients.
Gianantonio, Rosti; Gabriele, Gugliotta; Fausto, Castagnetti
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11585/613087
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact